Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552370 | 0.88 | DRD2 (0.53) | SMN1; SMN2GPR119MEN1KMT2ASCN9A | |
| SCHEMBL27651112 | 0.87 | PTGDR2 (0.47) | MEN1KMT2A | |
| SCHEMBL4853312 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2GPR119MEN1KMT2AKDM4E | |
| SCHEMBL26781329 | 0.83 | CHRM4 (0.60) | SMN1; SMN2GPR119MMP13SCN9ASTS | |
| SCHEMBL19103517 | 0.81 | PDE4B (0.48) | GPR119KDM4EMAPTTHRBSTS | |
| SCHEMBL17229874 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2GPR119MEN1KMT2AKDM4E | |
| SCHEMBL3542717 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2GPR119MEN1KMT2AKDM4E | |
| SCHEMBL17223034 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2GPR119MEN1KMT2AKDM4E | |
| SCHEMBL21523707 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2GPR119MEN1KMT2AKDM4E | |
| SCHEMBL20438978 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2GPR119MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698620-B1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | EISAI R&D MAN CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-7425554-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425554-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH1 | SMN1; SMN2 2729/4885GPR119 323/4885MMP13 785/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | SMN1; SMN2 2692/4885GPR119 281/4885MMP13 627/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | SMN1; SMN2 1754/4885GPR119 638/4885MMP13 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.